

Article

Not peer-reviewed version

A Novel In Vitro Potency Assay Demonstrating the Anti-Fibrotic Mechanism of Action of CDCs in Deramioce

[Yujia Li](#) , [Justin B. Nice](#) , [Marya Kozinova](#) , [Stephanie Adachi](#) , Linda Marbán , Kristi Elliott , [Minghao Sun](#) *

Posted Date: 7 October 2025

doi: 10.20944/preprints202510.0514.v1

Keywords: Deramioce; in vitro assay; anti-fibrotic activity; anti-fibrosis



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Article

A Novel In Vitro Potency Assay Demonstrating the Anti-Fibrotic Mechanism of Action of CDCs in Deramioce

Yujia Li, Justin B. Nice, Marya Kozinova, Stephanie Adachi, Linda Marbán, Kristi Elliott and Minghao Sun *

Capricor Therapeutics, Inc., 10865 Road to the Cure, San Diego, CA 92121, USA

* Correspondence: msun@capricor.com

Abstract

Duchenne muscular dystrophy (DMD) is characterized by progressive skeletal and cardiac muscle degeneration driven by inflammation and fibrosis, ultimately leading to cardiomyopathy and premature death. Deramioce, an allogeneic cell therapy composed of cardiosphere-derived cells (CDCs), has demonstrated potent anti-fibrotic and immunomodulatory effects in preclinical models and clinical trials, including HOPE-2 and its open-label extension (HOPE-2 OLE), where Deramioce treatment significantly attenuated progression of skeletal and cardiac muscle dysfunction. Here, we describe the development of a novel in vitro potency assay to quantify the anti-fibrotic activity of Deramioce. Conditioned media (CM) from multiple Deramioce manufacturing lots significantly suppressed expression of collagen type I alpha 1 (COL1A1) and collagen type III alpha 1 (COL3A1) in primary human dermal fibroblasts compared with non-conditioned media controls, establishing a robust, reproducible readout of anti-fibrotic activity. The effect was dose-dependent and abrogated by sequential depletion of exosomes and soluble proteins, implicating both as critical mediators of Deramioce's mechanism of action. Importantly, CDCs in deramioce lots classified as potent by this assay were shown to exert a clinically meaningful benefit in DMD patients in the HOPE-2 and HOPE-2 OLE studies. This assay represents a mechanistically informative, therapeutically relevant, reproducible, scalable, and regulatory-compliant approach for assessing Deramioce potency, enabling consistent manufacturing and facilitating the continued development of Deramioce as a disease-modifying therapy for DMD.

Keywords: Deramioce; in vitro assay; anti-fibrotic activity; anti-fibrosis

1. Introduction

Duchenne muscular dystrophy (DMD) is a severe, X-linked disease caused by mutations in the dystrophin gene resulting in progressive skeletal and cardiac muscle degeneration. The pathophysiology of DMD is such that the absence of dystrophin leads to accelerated injury to muscle cells resulting in a continuous cycle of muscle breakdown followed by inflammation and fibrosis. Early fibrosis is subsequently replaced by fibrofatty scar tissue as the disease progresses leading to both skeletal and cardiac muscle dysfunction as shown in Figure 1 [1]. This fibrofatty, non-contractile scarring of the myocardium leads to progressive weakening of the heart muscle, in particular the left ventricle, resulting in ever worsening cardiomyopathy. Cardiomyopathy is a universal feature of DMD and is the leading cause of death in DMD [2]. Thus, while new therapies have focused on restoration of dystrophin to address the primary disease, it is equally important to treat the inflammation and fibrosis that occurs in conjunction with the constant breakdown of muscle to preserve muscle function.




Figure 1. Pathophysiological progression of Duchenne muscular dystrophy (DMD) begins with a genetically caused deficiency in dystrophin expression. During normal muscle use, the absence of dystrophin renders muscle cells unable to recover from mechanical stress, leading to repeated cellular injury. This triggers an inflammatory cascade that promotes fibrosis and scar formation. Over time, non-contractile scar tissue replaces functional muscle, driving progressive muscle dysfunction, motor function loss, and cardiomyopathy.

Deramioceel is a human allogeneic cell therapy containing cardiosphere-derived cells (CDCs) derived from heart tissue which has been shown in numerous publications to have anti-fibrotic and immunomodulatory activity, which in turn aids in muscle survival and regeneration [3–6]. CDCs were originally developed as therapeutic agent for myocardial infarction and cardiac dysfunction [7]. In early clinical trials focused on myocardial infarction, the efficacy of CDCs was demonstrated by a reduction in fibrotic scar size in infarcted hearts using contrast-enhanced cardiac MRI [8].

Evidence of the efficacy and bioactivity of CDCs to treat DMD first arose in several nonclinical studies (unpublished; [9]) using the *mdx* mouse model which mimics the skeletal, respiratory, and cardiac dysfunction in DMD [10,11]. In these studies, CDCs were shown to improve skeletal muscle function as demonstrated by improved exercise capacity. Importantly, CDC treatment improved global cardiac function, similar to efficacy demonstrated in preclinical models and early clinical trials. Analysis of ejection fraction (EF) in the *mdx* mouse model after treatment with CDCs showed that EF improved within 3 weeks of treatment, driven largely by improvements in end-systolic volume (unpublished; [9]). In contrast, vehicle-treated mice continued to decline. The overall results of the studies showed that the baseline EF was sustained in CDC-treated mice (2 administrations) over a 6-month period. Importantly, a statistically significant reduction in myocardial fibrosis was observed in CDC-treated *mdx* mice as evidenced by reductions in both histological fibrosis and collagen content in the hearts of mice treated with CDCs. This reduction in fibrosis observed *in vivo* in CDC-treated hearts clearly demonstrates the anti-fibrotic mechanism of action of CDCs, aligning with published literature.

Data from the first clinical trial in DMD, the HOPE-Duchenne clinical trial, provided further evidence that CDCs, the active ingredient in Deramioceel, have anti-fibrotic activity as shown by a reduction in cardiac scarring and overall improvement in both cardiac and skeletal muscle function in DMD patients. Likewise, data from the HOPE-2, phase 2 randomized double-blind and placebo-controlled clinical trial, published in LANCET, demonstrated that DMD patients treated with Deramioceel over 12 months experienced significant attenuation of disease progression. Skeletal muscle function, as measured by mid-level performance of upper limb (PUL), showed a 71% slowing of decline ($p=0.014$). Importantly, the HOPE-2 trial showed significant preservation of cardiac function across multiple cardiac endpoints, including a 107% slowing of cardiac disease progression as measured by left ventricular ejection fraction (LVEF) ($p=0.002$). The preservation of cardiac function with Deramioceel treatment is likely a result of the reduction in inflammation and fibrosis imparted by CDCs which in turn results in reduced non-contractile scarring of the myocardium.

Together, these findings highlight the clinically meaningful and statistically significant therapeutic benefit of Deramiciol [2,12].

Following the HOPE-2 trial, 13 patients continued on open-label treatment with Deramiciol for up to 48 months. The therapeutic benefit of Deramiciol was maintained in both cardiac and skeletal muscle function. Skeletal muscle outcomes, assessed by PUL 2.0, showed a consistent reduction in disease progression: the mean decline was 1.8 points in Year 1, 1.2 points in Year 2, 1.1 points in Year 3, and 0.6 points in Year 4. Among 10 patients with centrally read cardiac MRI assessments, the median change in LVEF after 48 months was strikingly only -0.5%, clearly demonstrating the long-term cardiac stability of DMD patients treated with Deramiciol. These findings provide strong evidence that long-term Deramiciol therapy can slow the progression of both skeletal and cardiac muscle disease in patients with DMD. The stabilization of cardiac function in DMD patients for over 4 years is unprecedented and provides an opportunity for improved quality of life and decreased mortality in DMD patients.

Exosomes isolated from CDCs have been shown to be necessary and sufficient for the bioactivity of CDCs. In fact, CDC exosomes alone were able to reproduce improvements in cardiac and skeletal myopathy observed with CDCs using mdx mice [13]. CDC exosomes have been demonstrated to track to sites of injury and to be rapidly taken up by cardiac and skeletal muscle cells following injury in multiple mouse studies (unpublished, [13]). CDC exosome treatment improved contractile force in mdx soleus muscles, reduced interstitial fibrosis, and preserved muscle architecture. Importantly, treatment with CDC exosomes reduced myocardial collagen content, reduced myocardial scarring and improved LVEF to the same levels as CDC treatment alone [14–16]. Consistent with these effects, collagen I and III levels were reduced in CDC exosome-treated mdx hearts [17]. In addition, the improvements in LVEF in the mouse model observed after CDC treatment were attenuated when exosome secretion was inhibited [14]. Similar therapeutic benefits have been observed in large-animal models, including reduced scarring, anti-fibrotic effects, and improved LVEF [16]. Mechanistically, this finding suggests that exosomes secreted by CDCs play a critical anti-fibrotic role in stabilizing muscle function through suppression of collagen expression [18].

Similarly, paracrine signaling via growth factor secretion by CDCs has been implicated in the immunomodulatory and anti-fibrotic mechanism of action of CDCs in published literature. CDCs have been shown to secrete large amounts of VEGF, HGF, TIMP-2, IGF-1, SDF-1, angiopoietin 2 and bFGF [19,20]. In particular, VEGF, reduces ischemia-driven fibroblast activation and plays an indirect yet significant anti-fibrotic role; HGF, inhibits TGF- β -induced fibroblast-to-myofibroblast transition and collagen deposition and acts as a potent anti-fibrotic cytokine; and TIMP-2, which, in combination with matrix metalloproteinases (MMPs), helps maintain a balanced extracellular matrix, supports scar remodeling, and prevents excessive collagen cross-linking [21]. Additionally, other factors such as IL-10 and IGF-1 were identified as indirect suppressors of fibrosis through their anti-inflammatory and pro-survival effects, respectively. The signaling of all of these secreted factors aligns with the anti-fibrotic activity of Deramiciol, suggesting that the soluble factors secreted by Deramiciol also play a critical role in its mechanism of action.

In this paper, an in vitro cell-based assay was developed and subsequently validated using conditioned media (CM) from Deramiciol to assess its anti-fibrotic activity. Our findings demonstrate that Deramiciol exerts quantifiable anti-fibrotic activity in vitro, mediated through exosome and soluble factors in a dose-dependent manner. The anti-fibrotic activity observed in vitro using this assay aligns with data from non-clinical pharmacodynamic studies and importantly the clinical trial results observed in HOPE-2 and HOPE-2 OLE. The validated cell-based anti-fibrosis assay employed herein offers a controlled and reproducible platform enabling a mechanistically informative assessment of Deramiciol's potency.

2. Materials and Methods

2.1. Cell Culture

Primary human dermal fibroblasts (HDFs) and human cardiac fibroblasts (HCFs; two donors) were obtained from PromoCell and ATCC, respectively. ATCC media to grow HDF and HCF were prepared according to manufacturer's recommendation (ATCC/ PCS-201-030 and ATCC/PCS-201-041). Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO₂. For Deramioce cell cells, they are cultured in our proprietary culture media with 20% of FBS and were maintained at 37 °C with 5% CO₂ and 5% O₂ with humidity.

2.2. Preparation of Conditioned Media

Human CDCs were thawed and seeded at 0.5×10^6 cells per T75 flask in standard growth medium. After 24 h, the medium was aspirated, cells were washed once with DPBS (Gibco/14040-133) and 22 mL of fresh culture medium was added. Flasks were incubated for 72 h, after which supernatant was collected and clarified by centrifugation at $300 \times g$ for 5 min followed by $3,000 \times g$ for 15 min. The resulting supernatant was filtered through a 0.22 µm Steriflip filter (ThermoFisher Scientific/569-0020), aliquoted into 15 mL tubes, and stored at -80 °C until use.

2.3. Preparation of Non-Conditioned Media with Varying FBS Concentrations

To generate non-conditioned control media, CDC growth medium was prepared with 5%, 10%, 15%, or 20% FBS while keeping all other components identical. Media were clarified by centrifugation at $300 \times g$ for 5 min and $3,000 \times g$ for 15 min, filtered through a 0.22 µm filter ThermoFisher Scientific/569-0020, aliquoted, and stored at -80 °C. Non conditioned media with 20% FBS serves as a control in each assay.

2.4. Positive Control for Anti-Fibrosis Assay

Recombinant human EGF (rh EGF) was used as a positive control to confirm assay functionality. rh EGF from the Endothelial Cell Growth Kit-BBE (ATCC/ PCS-100-040) was diluted 1:500 into non-conditioned medium immediately prior to use.

2.5. Treatment of Human Dermal Fibroblasts (HDFs)

HDFs were seeded at 2.5×10^4 cells per well in 24-well plates and cultured overnight. The following treatment groups were applied: (i) Deramioce CM, (ii) non-conditioned control medium, and (iii) CM from human cardiac fibroblasts. For dose-response experiments, Deramioce CM was serially diluted (1:2, 1:5, 1:100) in non-conditioned medium. rh EGF was included in selected experiments as a positive control.

2.6. Exosome Depletion and Filtration Studies

To dissect the contribution of exosomes and soluble protein factors to the anti-fibrotic activity of Deramioce CM, sequential filtration was performed. CM from two independent manufacturing lots (LOT-0193 and LOT-0196) was processed using Amicon Ultra centrifugal filters (MilliporeSigma/ UFC8010 and UFC8100) with molecular weight cut-offs of 100 kDa and 10 kDa. For exosome depletion, CM was passed through a 100 kDa filter, and both the retentate (enriched in exosomes) and flow-through (exosome-depleted fraction) were collected and tested for biological activity in anti-fibrosis assays. For further resolution, CM was sequentially filtered through 100 kDa and 10 kDa cut-offs, yielding a 100 kDa retentate (exosome-enriched), a 100 kDa flow-through (exosome-depleted), and a 10 kDa flow-through (depleted of both exosomes and most soluble proteins). Each fraction, along with unprocessed CM and non-conditioned medium, was evaluated in the anti-fibrosis assay, with rh EGF included as positive control.

2.7. RNA Extraction and qRT-PCR

After 72 h of treatment, total HDF RNA was extracted using the RNeasy Micro Kit (Qiagen/74004 and 79656) according to the manufacturer's instructions. RNA concentration and purity were measured using a NanoDrop spectrophotometer (Thermo Fisher). To proceed with cDNA synthesis the RNA concentration must be ≥ 20 ng/ μ L and the A260/A280 between 1.8-2. Complementary DNA (cDNA) was synthesized from RNA using the iScript cDNA Synthesis Kit (Bio-Rad/1708891) according to the manufacturer's instructions. qRT-PCR was performed using TaqMan Gene Expression Mastermix (Applied Biosystems/4369016) on a QuantStudio 7 Flex Real-Time PCR System (Thermo Fisher). qPCR probes for COL1A1 (FAM), COL3A1 (FAM) and GAPDH (VIC) were ordered (Thermo Fisher). GAPDH was used as a housekeeping control. Relative expression levels were calculated using the $2^{-\Delta\Delta C_t}$ method against NCM. As part of the assay qualification and validation qPCR suitability criteria were established. A standard curve must show a slope of -3.2 to -3.9, technical triplicates must have a SD ≤ 0.5 (one may be removed from analysis). No-template control samples must have a $C_q \geq 35$ /undetermined. Biological triplicates must have a standard deviation of $C_q \leq 20\%$. Lastly, the positive control (rh EGF) must show $\leq 50\%$ relative gene expression for COL1A and COL3A.

2.8. Legendplex Flow Assay

Further characterization of secreted factors was done using the LEGENDplex™ Human Angiogenesis Panel 1 (Biolegend/741214). Non-conditioned media and conditioned media from three Deramioceel lots were incubated per the manufacturer's instructions undiluted and diluted 1:1. The beads were gated based on scattering and the fcs files were analyzed using the LEGENDplex™ online software. The level of expression of the secreted factors in Deramioceel conditioned media was normalized to non-conditioned media.

2.9. Statistical Analysis

All assays were performed in biological triplicates, with data expressed as mean $\pm$ standard deviation (SD). Statistical analyses were conducted using GraphPad Prism 9.1. Comparisons between groups were performed using one-way ANOVA followed by post-hoc correction for multiple comparisons or 2-tailed t-test were applied as needed. p-values < 0.05 were considered statistically significant, and significance levels were denoted as follows: **** $p < 0.0001$; *** $p < 0.0005$; ** $p < 0.001$; * $p < 0.05$; ns=not significant.

For the established assay, the historical performance of up to 32 HOPE-2 and HOPE-2 OLE clinical lots (with up to 36 months of clinical data at the time of analysis) and up to 58 additional lots tested across as many as five fibroblast working cell banks derived from a single donor was analyzed to set the acceptance criteria for the antifibrotic potency assay. COL1A and COL3A inhibition values were log2-transformed and evaluated for normality. Data from the working cell banks were combined using weighted means and standard deviations to generate donor-specific thresholds, with acceptance criteria defined as the pooled mean minus three standard deviations for each marker (COL1A and COL3A). For presentation purposes, these inhibition-based thresholds were converted to equivalent relative expression levels.

3. Results

3.1. Anti-Fibrotic Activity of CDCs in Deramioceel Correlates with Preclinical and Clinical Potency

To evaluate the anti-fibrotic activity of CDCs, an in vitro assay was developed using a co-culture system of fibroblasts with conditioned media (CM) collected from CDCs in Deramioceel (Figure 2). Briefly, CDCs in Deramioceel were cultured to generate CM enriched with secreted exosomes and factors, which was subsequently applied to primary human dermal fibroblasts (HDFs). HDFs were selected as the reporter cell line because fibroblasts are the principal effector cells in fibrosis and dermal fibroblasts provide a reproducible, well-characterized, and scalable system for in vitro testing.

Following co-culture, expression of collagen type I alpha 1 (COL1A1) and collagen type III alpha 1 (COL3A1) was measured by qRT-PCR. These genes were chosen as readouts because they represent the major extracellular matrix proteins deposited during fibrotic remodeling and are widely recognized biomarkers of fibroblast activation. Non-conditioned media serves as a control in the assay. Reduction in COL1A and COL3A expression therefore provides a direct and clinically relevant measure of the anti-fibrotic activity of Deramioceol.

The bioactivity of three Deramioceol lots, LOT-0121 (utilized in the HOPE-2 trial), LOT-0144 (utilized in the HOPE-2 open-label extension [OLE]), and LOT-0100 (not yet tested clinically), were initially assessed in the anti-fibrosis assay. As shown in Figure 3, conditioned media collected from all three lots of Deramioceol significantly reduced the expression of both COL1A and COL3A compared with the non-conditioned media control (NCM). Notably, the two lots employed in HOPE-2 and HOPE-2 OLE were classified as potent both in the anti-fibrosis assay and in the mouse myocardial infarction (MI) model and were also demonstrated to be clinically effective. Thus, the anti-fibrotic activity as demonstrated by the reduction in collagen expression observed with these two deramioceol lots is consistent with potency classified by the in vivo MI mouse model and with clinical potency.




Figure 2. Workflow of the anti-fibrosis potency assay. An in vitro assay was developed using a co-culture system of fibroblasts with conditioned media (CM) collected from CDCs in Deramioceol. Following co-culture, expression of collagen type I alpha 1 (COL1A1) and collagen type III alpha 1 (COL3A1) was measured by qRT-PCR.




Figure 3. Initial testing of three independent Deramioceel lots. Significant reduction of collagen gene expression (*COL1A*, *COL3A*) was observed in fibroblasts following co-culture with Deramioceel conditioned media (CM) compared to non-conditioned media (NCM) control (set at 0%, no inhibition). Assays were performed in triplicate, and data are presented as mean ± SD, normalized to NCM. Statistical significance: **** $p<0.0001$, *** $p<0.0005$, ** $p<0.001$.

Building on these findings, 11 additional lots of Deramioceel were subsequently evaluated, including LOT-0144 (used in HOPE-2 OLE; repeated for reproducibility), LOT-0124 (used in HOPE-2), LOT-0139 (used in HOPE-2 OLE), and LOT-0147 (used in HOPE-2 OLE). As shown in Figure 4, CM from all 11 lots significantly decreased *COL1A* (left panel) and *COL3A* (right panel) expression relative to the non-conditioned media (NCM) control. Importantly, results obtained with LOT-0144 were reproducible in this independent study, further demonstrating the reproducibility of the assay. Consistent with earlier observations, the four lots used clinically in HOPE-2 or HOPE-2 OLE were classified as potent in the mouse MI model and were shown to be effective clinically. Collectively, the anti-fibrotic activity as demonstrated by the reduction in collagen expression induced by these four deramioceel lots is consistent with potency classified by the in vivo mouse MI model and with clinical potency.




Figure 4. Reduction of collagen gene expression (*COL1A*, left panel; *COL3A*, right panel) in fibroblasts after co-culture with CM from 11 Deramioceel lots compared to NCM control (Set as 0%, no inhibition). Assays were performed in triplicate, and data are presented as mean ± SD, normalized to NCM. A representative statistical comparison is shown for the lot with the least reduction in collagen expression relative to NCM (**** $p<0.0001$).

To confirm data presented in Figure 4, independent vials of deramioceel were thawed and CM collected for evaluation in an independent anti-fibrosis assay (data not shown). CM collected from all repeats lots induced a statistically significant reduction in both *COL1A* and *COL3A* expression when compared to the non-conditioned media (NCM) control; demonstrating that the assay and data are consistent and reproducible.

3.2. Anti-Fibrotic Effect Is Attributed to Deramioceel Secreted Factors

To ensure that the anti-fibrotic activity observed in these studies was not due to protein or nutrient depletion in the conditioned media, the effect of reduced fetal bovine serum (FBS) concentrations was evaluated to mimic potential nutrient loss in CDC media. As shown in Figure 5, decreasing FBS concentrations from 20% to 5% in non-conditioned CDC media (NCM) resulted in increased expression of both *COL1A* and *COL3A*, as measured by qRT-PCR. These findings indicate that the reduction in collagen expression is not caused by protein or nutrient loss. Furthermore, the data supports the conclusion that the anti-fibrotic effect is primarily mediated by bioactive factors secreted by CDCs in Deramioceel, such as exosomes and growth factors.




Figure 5. Anti-fibrotic effect is not caused by protein or nutrient depletion from non-conditioned media (NCM). Fibroblasts were cultured with NCM containing decreasing concentrations of FBS to mimic nutrient loss. Assays were performed in triplicate, and data are presented as mean $\pm$ SD, normalized to 20% NCM.

3.3. Assay Specificity Demonstrated Using Non-Deramiocel Cells

To evaluate the specificity of the assay, conditioned media (CM) from non-CDC cells was tested. Human cardiac fibroblasts (HCF) were selected to evaluate in the assay since they are also derived from human hearts. Note that other cells from the heart could not be evaluated in the assay due to the inability of those cells to grow in CDC media required for the assay. As shown in Figure 6, CM from primary HCFs derived from two donors did not inhibit *COL1A* or *COL3A* expression relative to the non-conditioned media (NCM) control, as assessed by qRT-PCR. Accordingly, these HCFs would be classified as non-potent due to the absence of anti-fibrotic activity, supporting the assay’s specificity for CDC-mediated effects.




Figure 6. Human cardiac fibroblast (HCF) CM from two donors does not inhibit collagen gene expression (*COL1A*, *COL3A*) in fibroblasts after co-culture, demonstrating lack of anti-fibrotic activity. Assays were performed in triplicate, and data are presented as mean $\pm$ SD, normalized to NCM.

3.4. Dose-Dependent Activity of Deramioce^l CM in the Anti-Fibrosis Assay

To demonstrate that the anti-fibrosis assay can detect changes in Deramioce^l conditioned media (CM), CM from CDCs in two Deramioce^l lots— LOT-0193 and LOT-0196—was serially diluted and evaluated in the assay. As shown in Figure 7, both lots exhibited dose-dependent inhibition of COL1A and COL3A expression. Non-diluted CM from both lots significantly suppressed collagen expression, confirming expected potency. Notably, increased dilution of both lots of CM resulted in less inhibition of COL1A and COL3A. At a CM dilution of 1:5 or higher, little inhibition of collagen was observed. These CMs would therefore be classified as non-potent. These results indicate that the assay is sensitive to changes in Deramioce^l CM, such as reduced secretion of exosomes or growth factors, which are characteristic of less potent cells. Collectively, these findings support that the anti-fibrotic effect is mediated by secreted factors from CDCs in Deramioce^l in a dose-dependent manner.

For this study, recombinant human EGF (rh EGF) was used as a positive control for anti-fibrotic activity. The selection of rh EGF was guided by our preliminary studies using conditioned media (CM) from other cell types, such as human primary aortic endothelial cells (HAECs). When HDFs were treated with HAEC CM, we noted inhibition of COL1A and COL3A expression. Systematic component dilution experiments identified rh EGF as the mediator of collagen inhibition, leading to its adoption as a positive control to monitor if the assay is working properly (data not shown). Mechanistically, EGF engagement of the EGFR signaling pathway is known to modulate fibroblast activity and suppress excessive collagen production. Previous studies have demonstrated that EGF downregulates type I procollagen mRNA and protein levels in cultured human fibroblasts [22]. Other cardiac cell types were excluded due to the presence of EGF in their media formulations.




Figure 7. Dose-dependent inhibition of collagen gene expression (*COL1A*, *COL3A*) by serial dilutions of Deramioceol CM. Fibroblasts were treated with CM from LOT-0193 (left panel) and LOT-0196 (right panel). NCM and rh EGF (Positive) served as controls. Assays were performed in triplicate, and data are presented as mean $\pm$ SD, normalized to NCM. CM significance is marked against NCM and the first dilution with a significant p-value against 100% CM is marked **** $p<0.0001$, *** $p<0.0005$, * $p<0.05$.

3.5. Exosomes and Soluble Proteins Are Responsible for Anti-Fibrotic Activity

Deramioceol conditioned media (CM) contains two major components: 1) exosomes (and potentially other extracellular vesicles) released by CDCs in Deramioceol, and 2) soluble proteins, including growth factors secreted by CDCs in Deramioceol. Both components have been shown to contribute to Deramioceol’s mechanism of action [14,21,23]. Data presented above clearly demonstrate that Deramioceol CM, containing exosomes and growth factors, has anti-fibrotic activity.

To determine which components in CM mediate this effect, the role of exosomes in collagen inhibition was investigated first. CM from Deramioceol LOT-0193 and LOT-0196 was filtered using an Amicon 100 kDa column, which retains extracellular vesicles, including exosomes, ensuring the flow-through is exosome-free. The bioactivity of the exosome-free flow-through was then assessed in the anti-fibrosis assay. As shown in Figure 8, the rh EGF positive control significantly inhibited COL1A and COL3A expression, confirming assay functionality. Importantly, exosome-free CM exhibited increased COL3A expression compared to CM containing exosomes (i.e., CM, without Amicon treatment), suggesting that exosomes contribute to collagen inhibition (Deramioceol LOT-0196, initial data not shown, subsequent studies shown in Figure 8). These experiments were repeated three times across two lots, consistently showing increased COL3A expression following exosome depletion. Notably, COL1A expression was reduced to similar levels with both CM and exosome-free CM, indicating a differential effect of exosomes on collagen isoforms. These data strongly suggest that exosomes present in CM play a role in COL3A inhibition.




Figure 8. Sequential filtration demonstrates contributions of exosomes and soluble proteins to anti-fibrotic activity. Fibroblasts were treated with CM containing exosomes, exosome-free CM, or protein- and exosome-free CM, compared to rh EGF and NCM controls. COL1A and COL3A expressions were measured by qRT-PCR. Assays were performed in triplicate, and data are presented as mean $\pm$ SD, normalized to NCM. **** $p < 0.0001$, * $p < 0.05$, ns=not significant.

To further dissect the contribution of soluble proteins in CDC CM in anti-fibrotic activity, CM from the same lots was sequentially filtered through an Amicon 100kDa column removing extracellular vesicles (e.g., exosomes), followed by a Amicon 10kDa column, which removes most soluble proteins (e.g., growth factors) from CM. Three fractions were collected from the sequential filtration: 1) exosomes retained in the 100 kDa filter, 2) exosome-free 100 kDa flow-through, and 3) exosome- and soluble protein-free 10 kDa flow-through. Bioactivity was assessed for each fraction alongside unfiltered CM. As expected, unfiltered CM significantly reduced COL1A ($p < 0.0001$) and COL3A ($p = 0.0038$) expression compared to non-conditioned media (Figure 8). Importantly, exosomes collected from the 100 kDa retentate induced a statistically significant reduction in both COL1A and COL3A expression compared to non-conditioned media. This reduction was not significantly

different from CM, suggesting that CDC exosomes are necessary and sufficient for the bioactivity of CDCs, in alignment with in vivo studies.

Exosome-free CM (100 kDa flow-through) exhibited increased COL3A expression relative to CM containing exosomes, consistent with the prior depletion study (described above). Finally, exosome- and protein-free CM (10 kDa flow-through) demonstrated increased COL1A and COL3A expression to levels approaching or exceeding non-conditioned media, indicating loss of anti-fibrotic activity and classifying these samples as non-potent.

Collectively, these sequential filtration studies clearly demonstrate that both exosomes and soluble proteins, including growth factors, present in Deramioce^l CM inhibit collagen expression and are responsible for the anti-fibrosis mechanism of action.

3.8. Secreted Proteins Are Involved in Anti-Fibrosis

Additionally, a multi-panel flow assay on deramioce^l CM used in the anti-fibrosis assay revealed specific factors associated with anti-fibrosis, immunomodulation, and muscle survival. Similar to the anti-fibrosis assay, CM was compared with non-conditioned media (NCM) in the flow panel. Six factors with known direct or indirect roles in anti-fibrosis were observed to have an increased signal compared with NCM and are summarized in Table 1. Growth factors (FGF, EGF, and VEGF) are involved in anti-fibrosis via inhibition of myofibroblast activation, attenuation of the inflammatory fibrotic pathway and reduction of hypoxia-driven fibrosis, respectively and have been shown to be anti-fibrotic following injury [24–27]. The cytokine IL-6 has been shown to be directly involved in the mechanism of action of CDCs by reducing myocardial scarring [28,29]. The chemokine CXCL8 (IL-8) is known to be immunomodulatory and has been shown to be associated with improved left-ventricle ejection fraction (LVEF) following injury [30]. PECAM-1 inhibits endothelial to mesenchymal transition thus maintaining vasculature and reduces chronic inflammatory cell infiltration which both indirectly inhibit fibrosis [31]. These results, in conjunction with the filtration studies above, provide further evidence that the anti-fibrotic bioactivity of CDCs in deramioce^l is mediated by exosomes and secreted soluble factors.

Table 1. Secreted factors known to play a role in the anti-fibrotic activity of Deramioce^l CM.

Factor	Category	Role in Anti-fibrosis, Immunomodulation, or Muscle Survival	Supporting Reference(s)
bFGF (FGF-2)	Growth factor	Potent anti-fibrotic; inhibits TGF-β–induced myofibroblast activation, preventing ECM production; promotes regeneration and tissue repair	[24,25]
EGF	Growth factor	Enhances tissue survival and repair, limiting scar formation; modulates immune cell recruitment, attenuating inflammatory fibrotic cascade	[26]
VEGF	Growth factor	Maintains vasculature and reduces hypoxia-driven fibrosis	[27]
IL-6	Cytokine	Limits cardiac fibrosis Reduces myocardial scarring	[28,29]
CXCL8 (IL-8)	Chemokine	Modulates immune response in heart Prevents chronic inflammation, Promotes cytokine release key to fibrotic regulation	[30]
PECA M-1	Adhesion molecule	Reduces chronic inflammatory cell infiltration resulting in reduced fibrosis, Role in anti-inflammatory signaling; supports vascular repair	[31]

3.9. Potency and Efficacy of CDCs in Deramioce^l Lots Utilized in Clinical Trials

Together, these findings demonstrate the anti-fibrotic activity of exosomes and soluble factors secreted by CDCs in deramiocel. The anti-fibrosis assay was subsequently qualified and validated as a potency assay to assess the bioactivity of CDCs in every lot Deramiocel for product release. Analysis of the anti-fibrotic activity of multiple clinical lots from the HOPE-2 trial and HOPE-2 open label extension study that have been shown to be clinical beneficial in DMD patients were used to set the acceptance criteria. Acceptance criteria for the anti-fibrosis potency assay correspond to <75% expression for COL1A and <72% expression for COL3A (equivalent to ≥25% and ≥28% inhibition, respectively) and were established based on historical lot performance across five working cell banks of reporter fibroblasts (data not shown).

The potency of Deramiocel lots administered in the HOPE-2 and HOPE-2 OLE studies was consistently observed in the anti-fibrosis assay with substantial reduction in expression of COL1A and COL3A observed in reporter fibroblasts after treatment with conditioned medium. Figure 9 presents expression values for the lots utilized in the HOPE-2 trial and HOPE-2 open label extension study. These trials demonstrated that DMD patients treated with Deramiocel experienced significant attenuation of disease progression, both in skeletal and muscle function. Importantly, long-term cardiac stability in DMD patients treated with Deramiocel was observed over 48 months in HOPE-2 OLE. This clinical effect, particularly in cardiac function, is attributable to the anti-fibrotic mechanism of action of CDCs as demonstrated in vitro by the anti-fibrosis potency assay. Thus the anti-fibrotic activity induced in vitro is consistent with clinical potency. The potency assay developed here was reviewed by FDA during regulatory interactions and was accepted as suitable for use as a potency assay for product release.




Figure 9. Deramiocecel batches: COL1A and COL3A expression, measured in the anti-fibrotic potency assay. Data are shown for lots used in HOPE-2, HOPE-2 OLE, HOPE-3 (clinical data not yet unblinded) and lots unassigned to a trial, utilized for technology transfer or pending assignment to a clinical trial. Acceptance criteria are 75% for COL1A and 72% for COL3A (not shown).

In addition, data from the anti-fibrosis potency assay from all clinical deramiocecel lots utilized in the ongoing HOPE-3 clinical trial, as well as lots that were not assigned to clinical trials, are shown in Figure 9. These data again demonstrate the consistent reduction in COL1 and COL3 by exosomes and soluble factors secreted by CDCs in deramiocecel. Importantly, the inhibition of COL1 and COL3 met the acceptance criteria, deeming all lots as potent. All lots presented in Figure 9 were derived from master cell banks generated from >10 donor hearts, underscoring the reproducibility of the deramiocecel manufacturing process. In total, conditioned media collected from CDCs in over 130 lots of deramiocecel were shown to induce a significant reduction in collagen when compared to non-conditioned media. The totality of this data demonstrates the potency of CDCs in deramiocecel and the anti-fibrotic mechanism of action of CDCs observed in vitro, in vivo in pharmacodynamic studies and importantly in clinical trials.

4. Discussion

In this study, we demonstrate that conditioned media (CM) derived from CDCs in Deramiocecel exerts robust anti-fibrotic activity in primary human fibroblasts. Across multiple independent lots, Deramiocecel CM consistently suppressed expression of COL1A1 and COL3A1, two canonical markers of extracellular matrix deposition, while non-conditioned media or cardiac fibroblast-derived CM had no effect. These findings support the notion that the paracrine secretome of cardiosphere-derived cells (CDCs) harbors potent anti-fibrotic factors and provide mechanistic evidence for the therapeutic potential of Deramiocecel.

Potency testing is defined as the ability of a product to achieve its intended therapeutic effect, demonstrated through appropriate laboratory assays (FDA guidelines and 21 CFR 600.3(s), 21 CFR 610.10). Regulations require that potency be assessed using in vitro or in vivo tests specifically designed for each product, ensuring a valid measure of therapeutic activity.

Initially, an in vivo myocardial infarction (MI) mouse model was utilized as a potency test for Deramiocecel. MI is characterized by ischemic cardiomyocyte loss followed by adverse remodeling, including scar formation and ventricular stiffening. A major contributor to this remodeling is the excessive deposition of type I and type III collagens (COL1A and COL3A), which are key drivers of fibrosis and impaired cardiac function. Data from this model was used to assess and select deramiocecel lots for use in early clinical studies and the completed HOPE-2 clinical trial. However, this model presents multiple limitations: it is labor-intensive, time-consuming (approximately several months per experiment), requires specialized surgical skills, relies on subjective echocardiographic measurements in small animals, and can yield variable, hard-to-validate results [32]. Moreover, the MI model does not replicate the progressive fibrosis characteristic of DMD-associated pathology [33,34]. Indeed, mdx mouse models, the most common DMD model, demonstrate only mild, non-progressive skeletal muscle degeneration and do not faithfully recapitulate human disease, further reducing relevance for predicting clinical potency [35]. Therefore, development of a reliable and robust in vitro assay was required to assess the potency of each lot of deramiocecel for product release.

Earlier work from the Marb n laboratory established that CDCs act largely through paracrine signaling rather than direct engraftment, with key mediators including epidermal growth factor (EGF), interleukin-6 (IL-6), and CXC chemokine ligand 8 (CXCL8/IL-8) [14,36,37]. In those studies, EGF secretion was linked to enhanced angiogenesis and cardioprotection, while IL-6 and CXCL8 contributed to immunomodulation and remodeling of the myocardial niche. Our results extend these insights by demonstrating a direct anti-fibrotic action of the Deramiocecel secretome, as evidenced by downregulation of collagen gene expression in dermal fibroblasts. Importantly, we show that this activity is dose-dependent, exosome-associated, and robust across donor fibroblasts and Deramiocecel

manufacturing lots, thereby strengthening the translational relevance of these findings [14,38]. Interestingly, we also detected high levels of IL6 and CXCL8 secretion in Legendplex Flow Assay, which aligns well with the Deramioceal identity release assay using IL6 and CXCL8 as readouts. The assay measures these factors in RNA isolated from Deramioceal cell lysate by qPCR and demonstrates a strong fold-increase versus the negative control fibroblast RNA. EGF, measured by the Legendplex assay is also used as a positive control in the anti-fibrosis assay, further indicating its importance in the Deramioceal anti-fibrosis pathway.

The observation that CDC exosomes alone can recapitulate the anti-fibrotic activity of CDC CM and that exosome depletion abrogated the anti-fibrotic effects of Deramioceal CM highlights the central role of exosomes as vehicles for paracrine signaling [14,36,38,39]. While prior reports emphasized soluble cytokines such as EGF [22], our data indicates that exosome-enclosed mediators may be the dominant contributors to the anti-fibrotic phenotype. Exosomes can encapsulate not only proteins such as IL-6 and CXCL8, but also microRNAs such as mi146a and mi148a [40–43] and other regulatory cargos that suppress fibroblast activation and reduce collagen expression [14,37,44]. Thus, Deramioceal exosomes may represent a convergent delivery system integrating both cytokine signaling and gene regulatory programs.

The inclusion of fibroblasts from multiple donors in our study also provides a novel perspective, addressing biological variability often overlooked in earlier single-donor experiments. The reproducibility of Deramioceal's anti-fibrotic effect across diverse fibroblast populations suggests that its paracrine activity is robust and donor-independent, an important consideration for clinical translation [36,38]. Furthermore, the observation that cardiac fibroblast-derived CM failed to attenuate collagen expression underscores the uniqueness of the Deramioceal secretome relative to fibroblast paracrine signaling [38,39].

Taken together, our work builds upon the foundation laid by the Marbán group by moving beyond descriptive profiling of CDC secreted factors to a functional demonstration of anti-fibrotic activity in primary fibroblasts. The innovation of our study lies in: 1) Establishing lot-to-lot consistency of Deramioceal CM in suppressing fibrosis-related gene expression. 2) Demonstrating that the effect is dose-dependent and exosome-associated, distinguishing Deramioceal from conventional soluble-factor therapy. 3) Providing evidence that cytokines previously linked to CDC function (EGF, IL-6, CXCL8) may participate in a broader anti-fibrotic signaling network when delivered via exosomes [14,37–39,44].

Importantly, the clinically meaningful improvements in cardiac and skeletal function observed in the HOPE-2 and HOPE-2-OLE clinical studies are directly attributable to the anti-fibrotic mechanism of action of CDCs in deramioceal. The anti-fibrotic activity of CDCs observed in the in vitro potency assay aligns with multiple in vivo pharmacodynamic studies in the mdx mouse model and large animal models, which demonstrate a decrease in fibrosis leading to a reduction in muscle scarring and consequently improved skeletal and cardiac muscle function. Importantly, the in vitro and in vivo anti-fibrotic mechanism of action of CDCs aligns with the therapeutic benefit observed in DMD patients after treatment with deramioceal. Thus, the validated cell-based anti-fibrosis assay employed herein offers a controlled and reproducible assay enabling a mechanistically informative assessment of Deramioceal's potency and a demonstration of the deramioceal drug product to achieve its intended therapeutic effect.

Author Contributions: Conceptualization, Yujia Li, Kristi Elliott and Minghao Sun; Data curation, Yujia Li and Marya Kozinova; Formal analysis, Yujia Li, Justin Nice, Marya Kozinova and Stephanie Adachi; Investigation, Yujia Li, Justin Nice and Stephanie Adachi; Methodology, Yujia Li, Justin Nice, Marya Kozinova, Kristi Elliott and Minghao Sun; Software, Marya Kozinova; Supervision, Yujia Li, Kristi Elliott and Minghao Sun; Writing – original draft, Yujia Li; Writing – review & editing, Yujia Li, Justin Nice, Marya Kozinova, Linda Marbán, Kristi Elliott and Minghao Sun.

Declaration of Competing Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Funding: Capricor Therapeutics, Inc. is a NASDAQ listed company (Nasdaq: CAPR) and receives its funding primarily through the issuances of stock. The capital raised provides support in the form of salaries for all authors and pays for the acquisition of study materials and supplies, but the specific investors did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Declaration of generative AI and AI-assisted technologies in the writing process: During the preparation of this work the author(s) used ChatGPT in order to improve language and readability, with caution. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

References

1. Breaux A, Lang SM, Wittekind S, et al. Cardiac histopathology in Duchenne muscular dystrophy demonstrates diffuse fibrofatty replacement of the myocardium. *J Am Heart Assoc.* 2024;13(22):e033862. doi:10.1161/JAHA.123.033862
2. Soslow JH, Xu M, Slaughter JC, et al. Cardiovascular Measures of All-Cause Mortality in Duchenne Muscular Dystrophy. *Circ Heart Fail.* 2023;16(8):e010040. doi:10.1161/CIRCHEARTFAILURE.122.010040
3. Gallet R, de Couto G, Simsolo E, et al. Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation. *JACC Basic Transl Sci.* 2016;1(1-2):14-28. doi:10.1016/j.jacbs.2016.01.003
4. Tseliou E, Fouad J, Reich H, et al. Fibroblasts Rendered Antifibrotic, Antiapoptotic, and Angiogenic by Priming With Cardiosphere-Derived Extracellular Membrane Vesicles. *J Am Coll Cardiol.* 2015;66(6):599-611. doi:10.1016/j.jacc.2015.05.068
5. Rogers RG, Li L, Peck K, et al. Cardiosphere-derived cells, with and without a biological scaffold, stimulate myogenesis and recovery of muscle function in mice with volumetric muscle loss. *Biomaterials.* 2021;274:120852. doi:10.1016/j.biomaterials.2021.120852
6. Marbán E. Breakthroughs in cell therapy for heart disease: focus on cardiosphere-derived cells. *Mayo Clin Proc.* 2014;89(6):850-858. doi:10.1016/j.mayocp.2014.02.014
7. Ashur C, Frishman WH. Cardiosphere-Derived Cells and Ischemic Heart Failure. *Cardiol Rev.* 2018;26(1):8-21. doi:10.1097/CRD.0000000000000173
8. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. *Lancet.* 2012;379(9819):895-904. doi:10.1016/S0140-6736(12)60195-0
9. Aminzadeh MA, Rogers RG, Fournier M, et al. Reversal of cardiac and skeletal manifestations of Duchenne muscular dystrophy by cardiosphere-derived cells and their exosomes in mdx [preprint]. *bioRxiv.* 2017. doi:10.1101/128900
10. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. *Proc Natl Acad Sci U S A.* 1984;81(4):1189-1192. doi:10.1073/pnas.81.4.1189
11. Partridge TA. The mdx mouse model as a surrogate for Duchenne muscular dystrophy. *FEBS J.* 2013;280(17):4177-4186. doi:10.1111/febs.12267
12. McDonald CM, Marbán E, Hendrix S, et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet.* 2022;399(10329):1049-1058. doi:10.1016/S0140-6736(22)00012-5
13. Ciullo A, Li C, Li L, et al. Biodistribution of unmodified cardiosphere-derived cell extracellular vesicles using single RNA tracing. *J Extracell Vesicles.* 2022;11(1):e12178. doi:10.1002/jev2.12178
14. Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. *Stem Cell Reports.* 2014;2(5):606-619. Published 2014 May 8. doi:10.1016/j.stemcr.2014.04.006
15. Barile L, Lionetti V, Cervio E, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. *Cardiovasc Res.* 2014;103(4):530-541. doi:10.1093/cvr/cvu167

16. Gallet R, Dawkins J, Valle J, et al. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. *Eur Heart J*. 2017;38(3):201-211. doi:10.1093/eurheartj/ehw240
17. Aminzadeh MA, Rogers RG, Fournier M, et al. Exosome-Mediated Benefits of Cell Therapy in Mouse and Human Models of Duchenne Muscular Dystrophy. *Stem Cell Reports*. 2018;10(3):942-955. doi:10.1016/j.stemcr.2018.01.023
18. Rogers RG, Fournier M, Sanchez L, et al. Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice. *JCI Insight*. 2019;4(7):e125754. Published 2019 Apr 4. doi:10.1172/jci.insight.125754
19. Li TS, Cheng K, Malliaras K, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. *J Am Coll Cardiol*. 2012;59(10):942-953. doi:10.1016/j.jacc.2011.11.029
20. Cheng K, Ibrahim A, Hensley MT, et al. Relative roles of CD90 and c-kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction. *J Am Heart Assoc*. 2014;3(5):e001260. Published 2014 Oct 9. doi:10.1161/JAHA.114.001260
21. Chimenti I, Smith RR, Li TS, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. *Circ Res*. 2010;106(5):971-980. doi:10.1161/CIRCRESAHA.109.210682
22. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Epidermal growth factor affects the synthesis and degradation of type I collagen in cultured human dermal fibroblasts. *Matrix Biol*. 2006;25(4):202-212. doi:10.1016/j.matbio.2005.12.002
23. Zhu J, Wang S, Yang D, Xu W, Qian H. Extracellular vesicles: emerging roles, biomarkers and therapeutic strategies in fibrotic diseases. *J Nanobiotechnology*. 2023;21(1):164. Published 2023 May 24. doi:10.1186/s12951-023-01921-3
24. Farooq M, Khan AW, Kim MS, Choi S. The Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration. *Cells*. 2021;10(11):3242. Published 2021 Nov 19. doi:10.3390/cells10113242
25. Fearon AE, Slabber CF, Kuklin A, et al. Fibroblast growth factor receptor 3 in hepatocytes protects from toxin-induced liver injury and fibrosis. *iScience*. 2021;24(10):103143. Published 2021 Sep 16. doi:10.1016/j.isci.2021.103143
26. Lai T, Li Y, Chen M, et al. Heparin-binding epidermal growth factor contributes to COPD disease severity by modulating airway fibrosis and pulmonary epithelial-mesenchymal transition. *Lab Invest*. 2018;98(9):1159-1169. doi:10.1038/s41374-018-0049-0
27. Murray LA, Habel DM, Hohmann M, et al. Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. *JCI Insight*. 2017;2(16):e92192. Published 2017 Aug 17. doi:10.1172/jci.insight.92192
28. Mayfield AE, Kanda P, Nantsios A, et al. Interleukin-6 Mediates Post-Infarct Repair by Cardiac Explant-Derived Stem Cells. *Theranostics*. 2017;7(19):4850-4861. Published 2017 Oct 17. doi:10.7150/thno.19435
29. Maxeiner H, Mufti S, Krehbiel N, et al. Interleukin-6 contributes to the paracrine effects of cardiospheres cultured from human, murine and rat hearts. *J Cell Physiol*. 2014;229(11):1681-1689. doi:10.1002/jcp.24613
30. Husebye T, Eritsland J, Arnesen H, et al. Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure. *PLoS One*. 2014;9(11):e112359. Published 2014 Nov 12. doi:10.1371/journal.pone.0112359
31. Privratsky JR, Paddock CM, Florey O, Newman DK, Muller WA, Newman PJ. Relative contribution of PECAM-1 adhesion and signaling to the maintenance of vascular integrity. *J Cell Sci*. 2011;124(Pt 9):1477-1485. doi:10.1242/jcs.082271
32. Lindsey ML, Brunt KR, Kirk JA, et al. Guidelines for in vivo mouse models of myocardial infarction. *Am J Physiol Heart Circ Physiol*. 2021;321(6):H1056-H1073. doi:10.1152/ajpheart.00459.2021
33. Frangogiannis NG. Cardiac fibrosis. *Cardiovasc Res*. 2021;117(6):1450-1488. doi:10.1093/cvr/cvaa324
34. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and

- Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. *Circulation*. 2006;113(14):1807-1816. doi:10.1161/CIRCULATIONAHA.106.174287
35. Spurney CF, Cha H-J, Sali A, Pandey GS, Pistilli E, Guerron AD, et al. (2010) Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β -4 in the Dystrophin Deficient Mouse. *PLoS ONE* 5(1): e8976. doi:10.1371/journal.pone.0008976
 36. Zubkova E, Dergilev K, Beloglazova I, et al. Paracrine Responses of Cardiosphere-Derived Cells to Cytokines and TLR Ligands: A Comparative Analysis. *International Journal of Molecular Sciences*. 2023; 24(24):17278. doi:10.3390/ijms242417278
 37. Femminò S, Bonelli F, Brizzi MF. Extracellular vesicles in cardiac repair and regeneration: Beyond stem-cell-based approaches. *Front Cell Dev Biol*. 2022;10:996887. Published 2022 Sep 2. doi:10.3389/fcell.2022.996887
 38. Kogan, PS., Wirth, F., Tomar, A. et al. Uncovering the molecular identity of cardiosphere-derived cells (CDCs) by single-cell RNA sequencing. *Basic Res Cardiol* 117, 11 (2022). doi:10.1007/s00395-022-00913-y
 39. Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. *PLoS One*. 2014;9(2):e88685. Published 2014 Feb 18. doi:10.1371/journal.pone.0088685
 40. Weber B, Sturm R, Henrich D, et al. Diagnostic and Prognostic Potential of Exosomal Cytokines IL-6 and IL-10 in Polytrauma Patients. *Int J Mol Sci*. 2023;24(14):11830. Published 2023 Jul 23. doi:10.3390/ijms241411830
 41. Xu F, Wang X, Huang Y, et al. Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8⁺ T cell. *Cell Rep*. 2023;42(11):113424. doi:10.1016/j.celrep.2023.113424
 42. Zhang Z, Zou X, Zhang R, et al. Human umbilical cord mesenchymal stem cell-derived exosomal miR-146a-5p reduces microglial-mediated neuroinflammation via suppression of the IRAK1/TRAF6 signaling pathway after ischemic stroke. *Aging (Albany NY)*. 2021;13(2):3060-3079. doi:10.18632/aging.202466
 43. Tian S, Zhou X, Zhang M, et al. Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6/STAT3 pathway in macrophages. *Stem Cell Res Ther*. 2022;13(1):330. Published 2022 Jul 20. doi:10.1186/s13287-022-03010-y
 44. Rogers RG, Ciullo A, Marbán E, Ibrahim AG. Extracellular Vesicles as Therapeutic Agents for Cardiac Fibrosis. *Front Physiol*. 2020;11:479. Published 2020 May 21. doi:10.3389/fphys.2020.00479

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.